Skip to main content

Keoni Kauwe II

Professor

4102 LSB
Provo, UT 84602

Research Interests

Dr. Kauwe's research leverages novel phenotypes and approaches to characterize the genetic architecture of Alzheimer’s disease with the ultimate goal of finding a cure.

Research in the lab also includes studies on prevention, diagnosis, and the genetic basis of rheumatic heart disease and the use of genomics to address evolutionary questions in several species of fish and reptiles.

Teaching Interests

Within the Department of Biology, Dr. Kauwe has taught Biology 130, Introduction to Biology and Biology 463, Genetics of Human Disease. He is also committed to providing high quality mentored research experiences in his lab. His research is designed to include significant contributions from BYU undergraduates. His students have authored and co-authored more than three dozen manuscripts and received many awards for their research efforts.

Honors and Awards

  • 2015 BYU Sponsored Research Award

Professional Citizenship

  • Other, Charleston Conference on Alzheimer's Disease (CCAD), 2019-10-01 - 2019-10-31 - Present
  • Board Member, Native Alzheimer's Disease Resource Center for Minority Aging Research (NAD-RCMAR), 2019-08-01 - 2019-08-31 - Present
  • Other, NIH PAR Panel: Social Epigenomics Research Focused on Minority Health and Health Disparities, 2018-03-01 - 2018-03-31 - Present
  • Reviewer, Ad Hoc Reviewer, Sêr Cymru II, 2018-01-01 - 2018-12-31 - Present
  • Member, Alzheimer's Disease Sequencing Project (Protective Variants Group), 2016-01-01 - 2016-12-31 - Present
  • Reviewer, Ad Hoc Reviewer, JAMA Neurology, 2015-01-01 - 2015-12-31 - Present
  • Member, Alzheimer's Disease Neuroimaging Initiative (Genetics Core), 2014-01-01 - 2014-12-31 - Present
  • Reviewer, Ad Hoc Reviewer, Nature Medicine, 2014-01-01 - 2014-12-31 - Present
  • Grant Proposal Reviewer, External, University of Utah Center on Aging, 2014-01-01 - 2014-12-31 - Present
  • Reviewer, Ad Hoc Reviewer, Human Molecular Genetics, 2013-01-01 - 2013-12-31 - Present
  • Reviewer, Ad Hoc Reviewer, Medical Principles and Practice, 2013-01-01 - 2013-12-31 - Present
  • Grant Proposal Reviewer, External, Nathan Shock Center for Excellence in the Basic Biology of Aging, 2013-01-01 - 2013-12-31 - Present
  • Other, SAGE Bionetworks, 2013-01-01 - 2013-01-31 - Present
  • Reviewer, Ad Hoc Reviewer, Translational Psychiatry, 2013-01-01 - 2013-12-31 - Present
  • Reviewer, Ad Hoc Reviewer, Archives of General Psychiatry, 2012-01-01 - 2012-12-31 - Present
  • Reviewer, Ad Hoc Reviewer, Biological Psychiatry, 2012-01-01 - 2012-12-31 - Present
  • Reviewer, Ad Hoc Reviewer, BMC Bioinformatics, 2012-01-01 - 2012-12-31 - Present
  • Reviewer, Ad Hoc Reviewer, Brain Imaging and Behavior, 2012-01-01 - 2012-12-31 - Present
  • Reviewer, Ad Hoc Reviewer, European Journal of Human Genetics, 2012-01-01 - 2012-12-31 - Present
  • Reviewer, Ad Hoc Reviewer, PeerJ, 2012-01-01 - 2012-12-31 - Present
  • Reviewer, Ad Hoc Reviewer, Pharmacogenomics, 2012-01-01 - 2012-12-31 - Present
  • Reviewer, Ad Hoc Reviewer, Science Translational Medicine, 2012-01-01 - 2012-12-31 - Present
  • Reviewer, Ad Hoc Reviewer, Alzheimer's Association, 2011-01-01 - 2011-01-31 - Present
  • Reviewer, Ad Hoc Reviewer, Alzheimer’s & Dementia, 2011-01-01 - 2011-12-31 - Present
  • Grant Proposal Reviewer, External, Department of Veteran’s Affairs, 2011-01-01 - 2011-12-31 - Present
  • Reviewer, Ad Hoc Reviewer, Frontiers in Neurogenetics, 2011-01-01 - 2011-12-31 - Present
  • Reviewer, Ad Hoc Reviewer, Neuroscience Letters, 2011-01-01 - 2011-12-31 - Present
  • Reviewer, Ad Hoc Reviewer, Proceedings of the National Academy of Sciences, 2011-01-01 - 2011-12-31 - Present
  • Grant Proposal Reviewer, External, Knight Alzheimer's Disease Research Center, 2010-11-01 - 2010-11-30 - Present
  • Reviewer, Ad Hoc Reviewer, The International Journal of Neuroscience, 2010-06-01 - 2010-06-30 - Present
  • Reviewer, Ad Hoc Reviewer, Dementia and Geriatric Cognitive Disorders, 2010-01-01 - 2010-01-31 - Present
  • Reviewer, Ad Hoc Reviewer, Molecular Psychiatry, 2010-01-01 - 2010-12-31 - Present
  • Reviewer, Ad Hoc Reviewer, Neurobiology of Aging, 2010-01-01 - 2010-01-31 - Present
  • Reviewer, Ad Hoc Reviewer, NeuroMolecular Medicine, 2010-01-01 - 2010-12-31 - Present
  • Reviewer, Ad Hoc Reviewer, PLoS Genetics, 2010-01-01 - 2010-01-31 - Present
  • Reviewer, Ad Hoc Reviewer, American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2009-01-01 - 2009-12-31 - Present
  • Reviewer, Ad Hoc Reviewer, PLoS ONE, 2009-01-01 - 2009-12-31 - Present
  • Reviewer, Ad Hoc Reviewer, Archives of Neurology, 2008-01-01 - 2008-12-31 - Present
  • Reviewer, Ad Hoc Reviewer, Bioinformatics, 2008-01-01 - 2008-12-31 - Present
  • Reviewer, Ad Hoc Reviewer, Molecular Ecology, 2008-01-01 - 2008-12-31 - Present
  • Reviewer, Ad Hoc Reviewer, Neuropsychiatric Genetics, 2008-01-01 - 2008-12-31 - Present
  • Reviewer, Ad Hoc Reviewer, The Journal of Alzheimer's disease, 2008-01-01 - 2008-12-31 - Present
  • Reviewer, Ad Hoc Reviewer, The Journal of Neurological Sciences, 2008-01-01 - 2008-12-31 - Present
  • Member, Alzheimer's Disease Genetics Consortium (Biomarker Group), 2007-01-01 - 2007-12-31 - Present
  • Member, Genetic and Environmental Risk in Alzheimer's Disease, 2006-01-01 - 2006-12-31 - Present
  • Committee/Council Member, National Institutes of Health AD Summit, 2015-01-01 - 2015-01-31 - 2015-03-01 - 2015-03-31
  • Grant Proposal Reviewer, External, BrightFocus Foundation, 2013-01-01 - 2013-12-31 - 2014-01-01 - 2014-12-31
  • Reviewer, Ad Hoc Reviewer, Alzheimer's Association , 2014-01-01 - 2014-01-31 - 2014-05-01 - 2014-05-31
  • Grant Proposal Reviewer, External, Austrian Science Fund, 2012-01-01 - 2012-12-31 - 2012-01-01 - 2012-12-31
  • Grant Proposal Reviewer, External, Alzheimer’s Society UK, 2011-01-01 - 2011-12-31 - 2012-01-01 - 2012-12-31
  • Grant Proposal Reviewer, External, NIH National Institute on Aging Neuroscience Study Section, 2009-01-01 - 2009-12-31 - 2012-01-01 - 2012-12-31
  • Grant Proposal Reviewer, External, Parkinson’s UK, 2011-01-01 - 2011-12-31 - 2011-01-01 - 2011-12-31
  • Grant Proposal Reviewer, External, Alzheimer's Association, 2009-01-01 - 2009-12-31 - 2010-01-01 - 2010-12-31
  • Reviewer, Ad Hoc Reviewer, Nathan Shock Center of Excellence Basic Biology of Aging, 2009-01-01 - 2009-12-31 - 2010-01-01 - 2010-12-31
  • Reviewer, Ad Hoc Reviewer, Veteran's Affairs Science Research and Development, 2009-01-01 - 2009-12-31 - 2009-01-01 - 2009-12-31

Courses Taught

2020

  • BIO 559R: Section 004
  • BIO 559R: Section 005
  • BIO 494R: Section 012
  • BIO 494R: Section 029
  • BIO 494R: Section 011
  • BIO 799R: Section 002
  • BIO 494R: Section 010
  • BIO 799R: Section 007
  • BIO 194 : Section 004
  • BIO 494R: Section 009
  • BIO 494R: Section 041

2019

  • BIO 799R: Section 008
  • BIO 494R: Section 010
  • BIO 494R: Section 030
  • NEURO 449R: Section 010
  • BIO 799R: Section 008
  • BIO 494R: Section 015
  • BIO 799R: Section 004
  • BIO 494R: Section 018
  • BIO 559R: Section 001
  • BIO 799R: Section 007
  • BIO 463 : Section 001
  • BIO 494R: Section 009
  • BIO 494R: Section 039

2018

  • BIO 799R: Section 010
  • BIO 494R: Section 010
  • BIO 799R: Section 008
  • BIO 699R: Section 001
  • BIO 494R: Section 015
  • BIO 799R: Section 004
  • BIO 494R: Section 018
  • BIO 494R: Section 025
  • BIO 130 : Section 001
  • BIO 130 : Section 002
  • BIO 130 : Section 003
  • BIO 130 : Section 004
  • BIO 130 : Section 006
  • BIO 799R: Section 007
  • BIO 463 : Section 001
  • IAS 369R: Section 001
  • BIO 699R: Section 007
  • BIO 494R: Section 010

2017

  • BIO 799R: Section 010
  • BIO 194: Section 1
  • BIO 699R: Section 14
  • BIO 494R: Section 011
  • BIO 559R: Section 1
  • BIO 494R: Section 015
  • IAS 399R: Section 007
  • BIO 559R: Section 1
  • BIO 559R: Section 7
  • BIO 559R: Section 001
  • BIO 130 : Section 001
  • BIO 130 : Section 002
  • BIO 130 : Section 003
  • BIO 130 : Section 004
  • IAS 369R: Section 004
  • BIO 699R: Section 7
  • BIO 494R: Section 010

2016

  • BIO 559R: Section 1
  • BIO 494R: Section 011
  • NEURO 449R: Section 25
  • BIO 559R: Section 001
  • BIO 494R: Section 15
  • BIO 559R: Section 001
  • BIO 559R: Section 6
  • BIO 165 : Section 001
  • BIO 494R: Section 19
  • BIO 559R: Section 001
  • BIO 130 : Section 005
  • BIO 130 : Section 006
  • BIO 130 : Section 007
  • BIO 130 : Section 008
  • BIO 130 : Section 009
  • BIO 130 : Section 010
  • BIO 463 : Section 001
  • BIO 494R: Section 011

2015

  • BIO 559R: Section 1
  • BIO 494R: Section 011
  • BIO 494R: Section 019
  • BIO 559R: Section 001
  • BIO 130 : Section 001
  • BIO 130 : Section 002
  • BIO 130 : Section 003
  • BIO 130 : Section 004
  • BIO 463 : Section 001
  • BIO 494R: Section 011
  • NEURO 449R: Section 011

2014

  • BIO 559R: Section 001
  • BIO 799R: Section 011
  • BIO 699R: Section 008
  • BIO 494R: Section 011
  • NEURO 449R: Section 029
  • BIO 559R: Section 004
  • BIO 799R: Section 021
  • BIO 699R: Section 011
  • BIO 559R: Section 001
  • BIO 799R: Section 004
  • BIO 494R: Section 019
  • BIO 559R: Section 002
  • BIO 130 : Section 001
  • BIO 130 : Section 002
  • BIO 130 : Section 003
  • BIO 130 : Section 004
  • BIO 130 : Section 005
  • BIO 130 : Section 006
  • BIO 799R: Section 007
  • BIO 494R: Section 011
  • NEURO 449R: Section 012

2013

  • BIO 559R: Section 001
  • BIO 799R: Section 011
  • BIO 494R: Section 005
  • NEURO 449R: Section 014
  • BIO 559R: Section 001
  • BIO 799R: Section 011
  • BIO 559R: Section 001
  • BIO 799R: Section 004
  • BIO 559R: Section 003
  • BIO 463 : Section 001
  • BIO 165 : Section 001
  • BIO 494R: Section 017
  • NEURO 449R: Section 013
  • BIO 695R: Section 001

2012

  • BIO 559R: Section 001
  • BIO 130 : Section 005
  • BIO 130 : Section 006
  • BIO 130 : Section 007
  • BIO 130 : Section 008
  • BIO 130 : Section 009
  • BIO 130 : Section 010
  • BIO 130 : Section 011
  • BIO 130 : Section 012
  • BIO 799R: Section 011
  • BIO 494R: Section 006
  • BIO 494R: Section 024
  • NEURO 496R: Section 006
  • BIO 799R: Section 011
  • BIO 799R: Section 005
  • BIO 494R: Section 019
  • BIO 559R: Section 006
  • BIO 463 : Section 001
  • BIO 494R: Section 017
  • NEURO 449R: Section 012

2011

  • BIO 559R: Section 001
  • BIO 130 : Section 005
  • BIO 130 : Section 006
  • BIO 130 : Section 007
  • BIO 130 : Section 008
  • BIO 494R: Section 006
  • LFSCI 494R: Section 003
  • BIO 559R: Section 002
  • BIO 494R: Section 016
  • BIO 559R: Section 005
  • BIO 494R: Section 019
  • BIO 559R: Section 006
  • BIO 463 : Section 001
  • BIO 494R: Section 020
  • PDBIO 120 : Section 004

2010

  • BIO 494R: Section 006
  • BIO 494R: Section 017
  • BIO 494R: Section 020
  • BIO 463 : Section 001
  • BIO 494R: Section 020
  • LFSCI 494R: Section 002

2009

  • BIO 494R: Section 006
  • LFSCI 494R: Section 022
  • PDBIO 120 : Section 001
  • BIO 494R: Section 017
  • BIO 494R: Section 020
  • LFSCI 494R: Section 002

2008

  • BIOL 0: Section 1
  • BIOL 0: Section 1

Publications

  • Pickett BD, Wallace EM, Ridge PG, Kauwe JSK. April (2nd Quarter/Spring), 2020. Lingering Taxonomic Challenges Hinder Conservation and Management of Global Bonefishes.
  • Sanders CL, Rattinger GB, DeBerard MS, Hammond AG, Wengreen H, Kauwe JSK, Buhusi M, Tschanz JT. September 6, 2019. Interaction between Physical Activity and Genes Related to Neurotrophin Signaling in Late-Life Cognitive Performance: The Cache County Study.
  • ME, Jensen TD, Jansen-West K, Sens JP, Reddy JS, Ridge PG, Kauwe JSK, Belzil V, Pregent L, Carrasquillo MM, et alMay 20, 2019. Systematic analysis of dark and camouflaged genes reveals disease-relevant genes hiding in plain sight. 1st ed.
  • Wright SM, Jensen SL, Cockriel KL, Davis B, Tschanz JT, Munger RG, Corcoran CD, Kauwe JSK. March 15, 2019. Association study of rs3846662 with Alzheimer's disease in a population-based cohort: the Cache County Study.
  • Cannon-Albright LA, Foster NL, Schliep K, Farnham JM, Teerlink CC, Kaddas H, Tschanz J, Corcoran C, Kauwe JSK. March 13, 2019. Relative risk for Alzheimer disease based on complete family history.
  • Patel D, Mez J, Vardarajan BN, Staley L, Chung J, Zhang X, Farrell JJ, Rynkiewicz MJ, Cannon-Albright LA, Teerlink CC, et alMarch 1, 2019. Association of Rare Coding Mutations With Alzheimer Disease and Other Dementias Among Adults of European Ancestry. 3rd ed.
  • Tavana JP, Jensen NO, Rosene M, Ridge PG, Kauwe JSK, Karch CM. December 28, 2018. RAB10: an Alzheimer's disease resilience locus and potential drug target. 14th ed.
  • Sexton CE, Ebbert M, Miller RH, Ferrel M, Tschanz JAT, Corcoran CD, Initiative ADN, Ridge PG, Kauwe JSK. 2018. Common DNA Variants Accurately Rank an Individual of Extreme Height.
  • Sassi C, Nalls MA, Ridge PG, Gibbs R, Lupton MK, Troakes C, Lunnon K, Al-Sarraj S, Brown KS, Medway C, et al2018. Mendelian adult-onset leukodystrophy genes in Alzheimer's disease: critical influence of CSF1R and NOTCH3.
  • Ridge PG, Kauwe JSK. 2018. Mitochondria and Alzheimer’s disease: the role of mitochondrial genetic variation.
  • Maxwell TJ, Corcoran C, Del-Aguila JL, Budde JP, Deming Y, Cruchaga C, Goate AM, Kauwe JSK. August 28, 2018. Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels. 1st ed.
  • Cannon-Albright LA, Dintelman S, Maness T, Cerny J, Thomas A, Backus S, Farnham JM, Teerlink CC, Contreras J, Kauwe JSK, et alAugust 1, 2018. Population genealogy resource shows evidence of familial clustering for Alzheimer disease. 4th ed.
  • Anttila V, Bulik-Sullivan B, Finucane HK, Walters RK, Bras J, Duncan L, Escott-Price V, Falcone GJ, Gormley P, Malik R, et alJune 22, 2018. Analysis of shared heritability in common disorders of the brain. 6395th ed.
  • Ridge PG, Wadsworth ME, Miller JB, Saykin AJ, Green RC, Initiative tADN, Kauwe JSK. April (2nd Quarter/Spring), 2018. Assembly of 809 whole mitochondrial genomes with clinical, imaging, and fluid biomarker phenotyping. 4th ed.
  • Averill LA, Averill CL, Staley LA, Osawa-Kirk JL, Kauwe JSK, Henri-Barrus P. 2017. The Opioid Abuse Risk Screener predicts aberrant same-day urine drug tests and 1-year controlled substance database checks: A brief report. 2nd ed.
  • Ridge PG, Karch CM, Hsu S, Arano I, Teerlink CC, Ebbert MTW, Murcia JDG, Farnham JM, Damato AR, Allen M, et alNovember 29, 2017. Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer’s disease resilience.
  • Sims R, Lee SJvd, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, Kunkle BW, Boland A, Raybould R, Bis JC, et alJuly (3rd Quarter/Summer) 17, 2017. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. 9th ed.
  • Huang KL, Marcora E, Pimenova AA, Narzo AFD, Kapoor M, Jin SC, Harari O, Bertelsen S, Fairfax BP, Czajkowski J, et alJune 19, 2017. A common haplotype lowers PU1 expression in myeloid cells and delays onset of Alzheimer's disease.
  • Anand S, Barnes JM, Young SA, Garcia DM, Tolley HD, Kauwe JSK, Graves SW. June 9, 2017. Discovery and confirmation of diagnostic serum lipid biomarkers for Alzheimer's disease using direct infusion mass spectrometry. 2017th ed.
  • Matyi J, Tschanz JT, Rattinger GB, Sanders C, Vernon EK, Corcoran C, Kauwe JSK, Buhusi M. May 12, 2017. Sex Differences in Risk for Alzheimer's Disease Related to Neurotrophin Gene Polymorphisms: The Cache County Memory Study. 12th ed.
  • Parks T, Mirabel MM, Kado J, Auckland K, Nowak J, Rautanen A, Mentzer AJ, Marijon E, Jouven X, Perman ML, et alMay 11, 2017. Association between a common immunoglobulin heavy chain allele and rheumatic heart disease risk in Oceania. 14946th ed.
  • Allen LB, Taylor FH, Kauwe AI, Larsen T, Hippen AA, Allen M, Kauwe JSK. May 4, 2017. Using the Health Belief Model to evaluate Samoan caregiver perceptions for rheumatic heart disease follow-up care. 3rd ed.
  • Deming Y, ZL, Kapoor M, Harari O, Del-Aguila JL, Black K, Carrell D, Cai Y, Fernandez MV, Budde J, et alMay 1, 2017. Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers. 5th ed.
  • Fardo DW, Katsumata Y, Kauwe JSK, Deming Y, Harari O, Cruchaga C, Nelson PT. April (2nd Quarter/Spring) 1, 2017. CSF protein changes associated with hippocampal sclerosis risk gene variants highlight impact of GRN/PGRN.
  • Steele NZ, Carr JS, Bonham LW, Geier EG, Damotte V, Miller ZA, Desikan RS, Boehme KL, Mukherjee S, Crane PK, et alMarch 28, 2017. Fine-mapping of the human leukocyte antigen locus as a risk factor for Alzheimer disease: A case-control study. 3rd ed.
  • Mukherjee S, Russell JC, Carr DT, Burgess JD, Allen M, Serie DJ, Boehme KL, Kauwe JSK, Naj AC, Fardo DW, et alFebruary 24, 2017. Systems biology approach to late-onset Alzheimer's disease genome-wide association study identifies novel candidate genes validated using brain expression data and Caenorhabditis elegans experiments.
  • Jun GR, Chung J, Mez J, Barber R, Beecham GW, Bennett DA, Buxbaum JD, Byrd GS, Carrasquillo MM, Crane PK, et alFebruary 7, 2017. Transethnic genome-wide scan identifies novel Alzheimer's disease loci.
  • Haddick PC, Larson JL, Rathore N, Bhangale TR, Phung QT, Srinivasan K, Hansen DV, Lill JR, Pericak-Vance MA, Haines J, et alJanuary (1st Quarter/Winter) 1, 2017. A Common Variant of IL-6R is Associated with Elevated IL-6 Pathway Activity in Alzheimer's Disease Brains. 3rd ed.
  • Jun G, Ibrahim-Verbaas CA, Vronskaya M, Lambert JC, Chung J, Naj AC, Kunkle BW, Wang LS, Bis JC, Bellenguez C, et al2016. A novel Alzheimer disease locus located near the gene encoding tau protein.
  • Deming Y, Xia J, Cai Y, Lord J, Holmans P, Bertelsen S, Holtzman D, Morris JC, Bales K, Pickering EH, et al2016. A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin.
  • Sassi C, Nalls MA, Ridge PG, Gibbs R, Ding J, Lupton MK, Troakes C, Lunnon K, Al-Sarraj S, Brown KS, et al2016. ABCA7 p G215S as potential protective factor for Alzheimer’s disease.
  • Ridge PG, Hoyt KB, Boehme K, Mukherjee S, Crane PK, Haines JL, Mayeux R, Farrer LA, Pericak-Vance MA, Schellenberg GD, et al2016. Assessment of the genetic variance of late-onset Alzheimer’s disease.
  • Allen GI, Amoroso N, Anghel C, Balagurusamy V, Bare CJ, Beaton D, Bellotti R, Bennett DA, Boehme K, Boutros PC, et al2016. Crowdsourced estimation of cognitive decline and resilience in Alzheimer’s disease.
  • Shah D, Rohlfing F, Anand S, Johnson WE, Alvarez MT, Cobell J, King J, Young SA, Kauwe JSK, Graves SW. 2016. Discovery and Subsequent Confirmation of Novel Serum Biomarkers Diagnosing Alzheimer’s Disease. 2nd ed.
  • Ebbert MT, Wadsworth ME, Staley LA, Hoyt KL, Pickett B, Miller J, Duce J, Kauwe JSK, Ridge PG. 2016. Evaluating the necessity of PCR duplicate removal from next-generation sequencing data and a comparison of approaches. Suppl 7th ed.
  • Kauwe JSK, Goate AM. 2016. Genes for a ‘Wellderly’ Life. 8th ed.
  • Deming Y, Xia J, Cai Y, Lord J, Del-Aguila JL, Fernandez MV, Carrell D, Black K, Budde J, Ma S, et al2016. Genetic studies of plasma analytes identify novel potential biomarkers for several complex traits. 18092nd ed.
  • Staley LA, Ebbert MT, Parker S, Bailey M, Ridge PG, Goate AM, Kauwe JSK. 2016. Genome-wide association study of prolactin levels in blood plasma and cerebrospinal fluid. Suppl 3rd ed.
  • Chapuis J, Flaig A, Grenier-Boley B, Eysert F, Pottiez V, Deloison G, Vandeputte A, Ayral AM, Mendes T, Desai S, et al2016. Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism. 6th ed.
  • Sassi C, Ridge PG, Nalls MA, Gibbs R, Ding J, Lupton MK, Troakes C, Lunnon K, Al-Sarraj S, Brown KS, et al2016. Influence of Coding Variability in APP-Aß Metabolism Genes in Sporadic Alzheimer’s Disease. 6th ed.
  • Ebbert MT, Boehme KL, Wadsworth ME, Staley LA, Initiative ftADN, Consortium ADG, Mukherjee S, Crane PK, Ridge PG, Kauwe JS. 2016. Interaction between variants in CLU and MS4A4E modulates Alzheimer’s disease risk.
  • Hippen AA, Ebbert MTW, Norton MC, Tschanz JT, Munger RG, Corcoran CD, Kauwe JSK. 2016. Presenilin E318G variant and Alzheimer’s disease risk: the Cache County study. Suppl 3rd ed.
  • Oldoni E, Fumagalli GG, Serpente M, Fenoglio C, Scarioni M, Arighi A, Bruno G, Talarico G, Confaloni A, Piscopo P, et al2016. PRNP P39L Variant is a Rare Cause of Frontotemporal Dementia in Italian Population.
  • Mez J, Mukherjee S, Thornton T, Fardo DW, Trittschuh E, Sutti S, Sherva R, Kauwe JSK, Naj AC, Beecham GW, et al2016. The executive prominent/memory prominent spectrum in Alzherimer’s disease is highly heritable.
  • Staley LA, Ebbert MT, Bunker D, Bailey M, Ridge PG, Goate AM, Kauwe JSK. 2016. Variants in ACPP are associated with cerebrospinal fluid Prostatic Acid Phosphatase levels. 3rd ed.
  • Ebbert MT, Staley LA, Parker J, Parker S, Bailey M, Ridge PG, Goate AM, Kauwe JSK. 2016. Variants in CCL16 are associated with blood plasma and cerebrospinal fluid CCL16 protein levels. 3rd ed.
  • Perry CE, Gale SD, Erickson LD, Wilson E, Nielsen B, Kauwe JSK, Hedges DW. April (2nd Quarter/Spring), 2016. Seroprevalence and Serointensity of Latent Toxoplasma gondii in a Sample of Elderly Adults With and Without Alzheimer Disease. 2nd ed.
  • Chen T, Moore TM, Ebbert MT, McVey NL, Madsen SR, Hallowell DM, Harris AM, Mackay RP, Char RE, Hancock CR, et alJanuary (1st Quarter/Winter), 2016. Liver kinase B1 inhibits the expression of inflammation-related genes post-contraction in skeletal muscle. 8th ed.
  • Ostergaard SD, Mukherjee S, Sharp SJ, Proitsi P, Lotta LA, Day F, Perry, Boehme K, Walter S, Kauwe JSK, et alOctober (4th Quarter/Autumn), 2015. Associations between Potentially Modifiable Risk Factors and Alzheimer Disease: A Mendelian Randomization Study. 6th ed.
  • Saykin AJ, Shen L, Yao X, Kim S, Nho K, Risacher SL, Ramanan VK, Foroud TM, Faber KM, Sarwar N, et al2015. Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans.
  • Mukherjee S, Walter S, Kauwe JSK, Saykin AJ, Bennett DA, Crane PK, Glymour MM. 2015. Genetically predicted body mass index and Alzheimer's disease-related phenotypes in three large samples: Mendelian randomization analyses. 12th ed.
  • Wang LS, Naj AC, Graham RR, Crane PK, Kunkle BW, Cruchaga C, Murcia JD, Cannon-Albright L, Baldwin CT, Zetterberg H, et al2015. Rarity of the Alzheimer disease-protective APP A673T variant in the United States. 2nd ed.
  • Lythgoe C, Perkes A, Peterson M, Schmutz C, Leary M, Ebbert MT, Ridge PG, Norton MC, Tschanz JT, Munger RG, et al2015. Population-based analysis of cholesteryl ester transfer protein identifies association between I405V and cognitive decline: the Cache County Study. 1st ed.
  • Ebbert MT, Ridge PG, Kauwe JS. May, 2015. Bridging the Gap between Statistical and Biological Epistasis in Alzheimer’s Disease.
  • Seeley M, Clement MJ, Giraud-Carrier CG, Snell QO, Bodily P, Fujimoto S, Kauwe JSK, Ridge PG. 2014. A Structured Approach to Ensemble Learning for Alzheimer’s Disease Prediction. New York, NY, USA: ACM.
  • Shen L, Thompson PM, Potkin SG, Bertram L, Farrer LA, Foroud TM, Green RC, Hu X, Huentelman MJ, Kim S, et al2014. Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers.
  • Dayton P, Kauwe M, Kauwe JSK, Feilmeier M, Hirschi J. 2014. Observed Changes in First Metatarsal and Medial Cuneiform Positions after First Metatarsophalangeal Joint Arthrodesis.
  • Ebbert MT, Ridge PG, Wilson AR, Sharp AR, Bailey M, Norton MC, Tschanz JT, Munger RG, Corcoran CD, Kauwe JSK. 2014. Population-based Analysis of Alzheimer’s Disease Risk Alleles Implicates Genetic Interactions. 9th ed.
  • Peterson D, Munger C, Crowley J, Corcoran C, Cruchaga C, Goate AM, Norton MC, Green RC, Initiative ADN, Munger RG, et al2014. Variants in PPP3R1 and MAPT are associated with more rapid functional decline in Alzheimer's disease: The Cache County Dementia Progression Study. 3rd ed.
  • Naj AC, Jun G, Reitz C, Kunkle BW, Perry W, Park YS, Beecham GW, Rajbhandary RA, Hamilton-Nelson KL, Wang LS, et alNovember 1, 2014. Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study. 11th ed.
  • Kauwe JSK, Bailey MH, Ridge PG, Perry R, Wadsworth ME, Hoyt KL, Staley LA, Karch CM, Harari O, Cruchaga C, et alOctober (4th Quarter/Autumn) 1, 2014. Genome-wide association study of CSF levels of 59 alzheimer's disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation. 10th ed.
  • Allen M, Kachadoorian M, Quicksall Z, Zou F, Chai HS, Younkin C, Crook JE, Pankratz VS, Carrasquillo MM, Krishnan S, et alJuly (3rd Quarter/Summer) 1, 2014. Association of MAPT haplotypes with Alzheimer's disease risk and MAPT brain gene expression levels. 39th ed.
  • Escott-Price V, Bellenguez C, Wang LS, Choi SH, Harold D, Jones L, Holmans P, Gerrish A, Vedernikov A, Richards A, et alJune 12, 2014. Gene-wide analysis detects two new susceptibility genes for Alzheimer's disease. 6th ed.
  • Benitez BA, Jin SC, Guerreiro R, Graham R, Lord J, Harold D, Sims R, Lambert JC, Gibbs JR, Bras J, et alJune 1, 2014. Missense variant in TREML2 protects against Alzheimer's disease. 6th ed.
  • Cruchaga C, Ebbert MT, Kauwe JSK. March 1, 2014. Genetic discoveries in AD using CSF amyloid and tau. 1st ed.
  • Dayton P, Feilmeier M, Hirschi J, Kauwe M, Kauwe JSK. February 20, 2014. Observed changes in radiographic measurements of the first ray after frontal plane rotation of the first metatarsal in a cadaveric foot model.
  • Cao Y, Wei P, Bailey M, Kauwe JSK, Maxwell TJ. January (1st Quarter/Winter), 2014. A versatile omnibus test for detecting mean and variance heterogeneity. 1st ed.
  • Cruchaga C, Karch CM, Jin SC, Benitez BA, Cai Y, Guerreiro R, Harari O, Norton J, Budde J, Bertelsen S, et alJanuary (1st Quarter/Winter) 23, 2014. Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. 7484th ed.
  • Harari O, Cruchaga C, Kauwe JSK, Ainscough BJ, Bales K, Pickering EH, Bertelsen S, Fagan AM, Holtzman DM, Morris JC, et alJanuary (1st Quarter/Winter) 19, 2014. Phosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage AD in multiplex immunoassay panels of cerebrospinal fluid.
  • Gross AL, Sherva R, Mukherjee S, Newhouse S, Kauwe JSK, Munsie LM, Waterston LB, Bennett DA, Jones RN, Green RC, et alJanuary (1st Quarter/Winter) 1, 2014. Calibrating longitudinal cognition in Alzheimer's disease across diverse test batteries and datasets. 3-4th ed.
  • Ridge PG, Maxwell TJ, Foutz SJ, Bailey MH, Corcoran CD, Tschanz JT, Norton MC, Munger RG, O'Brien E, Kerber RA, et alJanuary (1st Quarter/Winter) 1, 2014. Mitochondrial genomic variation associated with higher mitochondrial copy number: the Cache County Study on Memory Health and Aging. Suppl 7th ed.
  • Sharp AR, Ridge PG, Bailey MH, Boehme KL, Norton MC, Tschanz JT, Munger RG, Corcoran CD, Kauwe JSK. January (1st Quarter/Winter) 1, 2014. Population substructure in Cache County, Utah: the Cache County study. Suppl 7th ed.
  • Ebbert MT, Wadsworth ME, Boehme KL, Hoyt KL, Sharp AR, O'Fallon BD, Kauwe JSK, Ridge PG. January (1st Quarter/Winter) 1, 2014. Variant Tool Chest: an improved tool to analyze and manipulate variant call format (VCF) files. Suppl 7th ed.
  • Murcia JDG, Schmutz C, Munger C, Perkes A, Gustin A, Peterson M, Ebbert MT, Norton MC, Tschanz JT, Munger RG, et alDecember, 2013. Assessment of TREM2 rs75932628 association with Alzheimer's disease in a population-based sample: the Cache County Study. 12th ed.
  • Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, DeStafano AL, Bis JC, Beecham GW, Grenier-Boley B, et alDecember 1, 2013. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. 12th ed.
  • Ridge PG, Mukherjee S, Crane PK, Kauwe JSK, ADGC. November 7, 2013. Alzheimer's disease: analyzing the missing heritability. 11th ed.
  • Kauwe JSK, Ridge PG, Foster NL, Cannon-Albright LA. October (4th Quarter/Autumn), 2013. Strong evidence for a genetic contribution to late-onset Alzheimer’s disease mortality: a population-based study. 10th ed.
  • Ridge PG, Koop A, Maxwell TJ, Bailey MH, Swerdlow RH, Kauwe JSK, Honea RA. September 11, 2013. Mitochondrial haplotypes associated with biomarkers for Alzheimer’s disease. 9th ed.
  • Ridge PG, Ebbert MT, Kauwe JSK. July (3rd Quarter/Summer), 2013. Genetics of Alzheimer’s disease. 254954th ed.
  • Cruchaga C, Kauwe JSK, Harari O, Jin SC, Cai Y, Karch CM, Benitez BA, Jeng AT, Skorupa T, Carrell D, et alApril (2nd Quarter/Spring) 24, 2013. GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. 2nd ed.
  • Houston DD, Elzinga DB, Maughan PJ, Smith SM, Kauwe JSK, Evans RP, Stinger RB, Shiozawa DK. December, 2012. Single nucleotide polymorphism discovery in cutthroat trout subspecies using genome reduction, barcoding, and 454 pyro-sequencing. 724th ed.
  • Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JSK, Younkin S, et alNovember, 2012. TREM2 Variants in AD. 2nd ed.
  • Ridge P, Maxwell T, Corcoran C, Norton M, Tschanz J, O'Brien E, Kerber R, Cawthon R, Munger R, Kauwe JSK. September, 2012. Mitochondrial genomic analysis of late onset Alzheimer's disease reveals protective haplogroups H6A1A/H6A1B: the Cache County Study on Memory in Aging. 9th ed.
  • Cruchaga C, Kauwe JSK, Nowotny P, Bales K, Pickering E, Mayo K, Bertelsen S, Hinrichs A, Initiative ADN, Fagan A, et alJuly (3rd Quarter/Summer), 2012. Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. 20th ed.
  • Gerrish A, Russo G, Richards A, Moskvina V, Ivanov D, Harold D, Sims R, Abraham R, Hollingworth P, Chapman J, et alJanuary (1st Quarter/Winter) 1, 2012. The role of variation at AβPP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease. 2nd ed.
  • Overton ET, Kauwe JSK, Paul R, Tashima K, Tate DF, Patel P, Carpenter CC, Patty D, Brooks JT, Clifford DB. November, 2011. Performances on the CogState and Standard Neuropsychological Batteries Among HIV Patients Without Dementia. 8th ed.
  • Cruchaga C, Nowotny P, Kauwe JSK, Ridge PG, Mayo K, Bertelsen S, Hinrichs A, Fagan AM, Holtzman DM, Morris JC, et alJuly (3rd Quarter/Summer), 2011. Association and Expression Analyses with Single Nucleotide Polymorphisms in TOMM40 in Alzheimer's disease. 8th ed.
  • Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, et alMay 1, 2011. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. 5th ed.
  • Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, et alMay 1, 2011. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. 5th ed.
  • Kauwe JSK, Cruchaga C, Karch CM, Sadler B, Lee M, Mayo K, Latu W, Su'a M, Fagan AM, Holtzman DM, et alFebruary, 2011. Fine Mapping of Genetic Variants in BIN1, CLU, CR1 and PICALM for Association with Cerebrospinal Fluid Biomarkers for Alzheimer's Disease. 2nd ed.
  • Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, Pocklington A, Abraham R, Hollingworth P, Sims R, et alDecember, 2010. Genetic Evidence Implicates the Immune System and Cholesterol Metabolism in the Aetiology of Alzheimer's Disease. 11th ed.
  • Kauwe JSK, Bertelsen S, Mayo K, Cruchaga C, Abraham R, Hollingworth P, Harold D, Owen MJ, Williams J, Lovestone S, et al2010. Suggestive synergy between genetic variants in TF and HFE as risk factors for AD. 4th ed.
  • Cruchaga C, Kauwe JSK, Mayo K, Spiegel N, Bertelsen S, Nowotny P, Shah AR, Abraham R, Hollingworth P, Harold D, et alSeptember, 2010. SNPs Associated with Cerebrospinal Fluid Phospho-Tau Levels Influence Rate of Decline in AD. 9th ed.
  • Kauwe JSK, Cruchaga SB, Mayo K, Latu W, Nowotny P, Hinrichs AL, Fagan AM, Holtzman DM, Neuroimaging IAD, Goate AM. July (3rd Quarter/Summer), 2010. Validating Predicted Biological Effects of Alzheimer's Disease Associated SNPs Using CSF Biomarker Levels. 3rd ed.
  • Clifford DB, Fagan AM, Holtzman DM, Morris JC, Teshome M, Shah AR, Kauwe JSK. November, 2009. CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease.
  • Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, et alSeptember, 2009. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease.
  • Fenoglio C, Galimberti D, Cortini F, Kauwe JSK, Cruchaga C, Venturelli E, Villa C, Serpente M, Scalabrini D, Mayo K, et alJuly (3rd Quarter/Summer), 2009. Rs5848 Variant Influences GRN mRNA Levels in Brain and Peripheral Mononuclear Cells in Patients with Alzheimer's Disease. 3rd ed.
  • Kauwe JSK, Wang J, Mayo K, Morris JC, Fagan AM, Holtzman DM, Goate AM. February, 2009. Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta. 1st ed.
  • Kauwe JSK, Wang J, Chakraverty S, Goate AM, Henao-Martinez AF. June, 2008. Novel presenilin 1 variant (P117A) causing Alzheimer's disease in the fourth decade of life.
  • Kauwe JSK, Cruchaga C, Mayo K, Fenoglio C, Bertelsen S, Nowotny P, Galimberti D, Scarpini E, Morris JC, Fagan AM, et alJune, 2008. Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition.
  • Mukherjee O, Wang J, Gitcho M, Chakraverty S, Taylor-Reinwald L, Shears S, Kauwe JSK, Norton J, Levitch D, Bigio EH, et alApril (2nd Quarter/Spring), 2008. Molecular characterization of novel progranulin (GRN) mutations in frontotemporal dementia.
  • Hu Y, Hosseini A, Kauwe JSK, Gross J, Cairns NJ, Goate AM, Fagan AM, Townsend RR, Holtzman DM. November 1, 2007. Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease. 11th ed.
  • Nowotny P, Simcock X, Bertelsen S, Hinrichs AL, Kauwe JSK, Mayo K, Smemo S, Morris JC, Goate A. June 5, 2007. Association studies testing for risk for late-onset Alzheimer's disease with common variants in the beta-amyloid precursor protein (APP). 4th ed.
  • Kauwe JSK, Jacquart S, Chakraverty S, Wang J, Mayo K, Fagan AM, Holtzman DM, Morris JC, Goate AM. May, 2007. Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation.
  • Nowotny P, Bertelsen S, Hinrichs AL, Kauwe JSK, Mayo K, Jacquart S, Morris JC, Goate A. May 23, 2007. Association studies between common variants in prolyl isomerase Pin1 and the risk for late-onset Alzheimer's disease. 1st ed.
  • Wahrle SE, Shah AR, Fagan AM, Smemo S, Kauwe JSK, Grupe A, Hinrichs A, Mayo K, Jiang H, Thal LJ, et alApril (2nd Quarter/Spring) 12, 2007. Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms.
  • Mukherjee O, Kauwe JSK, Mayo K, Morris JC, Goate AM. January (1st Quarter/Winter) 31, 2007. Haplotype-based association analysis of the MAPT locus in late onset Alzheimer's disease.
  • YL, Grupe A, Rowland C, Nowotny P, Kauwe JSK, Smemo S, Hinrichs A, Tacey K, Toombs TA, Kwok S, et alSeptember 1, 2006. DAPK1 variants are associated with Alzheimer's disease and allele-specific expression. 17th ed.
  • Mukherjee O, Pastor P, Cairns NJ, Chakraverty S, Kauwe JSK, Shears S, Behrens MI, Budde J, Hinrichs AL, Norton J, et alSeptember 1, 2006. HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin. 3rd ed.
  • Grupe A, YL, Rowland C, Nowotny P, Hinrichs AL, Smemo S, Kauwe JSK, Maxwell TA, Cherny S, Doil L, et alJanuary (1st Quarter/Winter) 1, 2006. A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer disease. 1st ed.
  • Smemo S, Nowotny P, Hinrichs AL, Kauwe JSK, Cherny S, Erickson K, Myers AJ, Kaleem M, Marlowe L, Gibson AM, et alJanuary (1st Quarter/Winter) 1, 2006. Ubiquilin 1 polymorphisms are not associated with late-onset Alzheimer's disease. 1st ed.
  • Suarez BK, Taylor C, Bertelsen S, Bierut LJ, Dunn G, Jin CH, Kauwe JSK, Paterson AD, Hinrichs AL. December 30, 2005. An analysis of identical single-nucleotide polymorphisms genotyped by two different platforms.
  • Dunn G, Hinrichs AL, Bertelsen S, Jin CH, Kauwe JSK, Suarez BK, Bierut LJ. December 30, 2005. Microsatellites versus single-nucleotide polymorphisms in linkage analysis for quantitative and qualitative measures.
  • Hinrichs AL, Bertelsen S, Bierut LJ, Dunn G, Jin CH, Kauwe JSK, Suarez BK. December 30, 2005. Multipoint identity-by-descent computations for single-point polymorphism and microsatellite maps.
  • Kauwe JSK, Bertelsen S, Bierut LJ, Dunn G, Hinrichs AL, Jin CH, Suarez BK. December 30, 2005. The efficacy of short tandem repeat polymorphisms versus single-nucleotide polymorphisms for resolving population structure.
  • Nowotny P, Hinrichs AL, Smemo S, Kauwe JSK, Maxwell T, Holmans P, Hamshere M, Turic D, Jehu L, Hollingworth P, et alJuly (3rd Quarter/Summer) 5, 2005. Association studies between risk for late-onset Alzheimer's disease and variants in insulin degrading enzyme. 1st ed.
  • YL, Nowotny P, Holmans P, Smemo S, Kauwe JSK, Hinrichs AL, Tacey K, Doil L, Luchene Rv, Garcia V, et alNovember 2, 2004. Association of late-onset Alzheimer's disease with genetic variation in multiple members of the GAPD gene family. 44th ed.
  • Kauwe JSK, Shiozawa DK, Evans RP. October (4th Quarter/Autumn), 2004. Phylogeographic and nested clade analysis of the stonefly Pteronarcys californica (Plecoptera) in the Western United States. 4th ed.

Presentations

  • Tavana J, Weber KS, Kauwe JSK. Autosomal Dominant Early Onset Alzheimer’s Disease in Pacific Island Populations. American Society of Microbiology Intermountain Branch Meeting . December, 2020.
  • Nelson A, Murcia JG, Dearden L, Weinert A, Freitas C, Ferrel M, Grose JH, Ridge PG, Wilson E, Kauwe JSK, et alThe CCRL2 atypical chemokine receptor variant V180M alters CCL4 secretion in leukocytes . American Society of Microbiology Intermountain Branch Meeting . December, 2020.
  • Dearden L, Murcia JG, Nelson A, Weinert A, Freitas C, Ferrel M, Grose JH, Ridge PG, Wilson E, Kauwe JSK, et alThe CCRL2 atypical chemokine receptor variant V180M has a higher binding affinity for chemerin . American Society of Microbiology Intermountain Branch Meeting . December, 2020.
  • Miller J, McKinnon LM, Murcia J, Black G, Ward E, Webster J, Kauwe JSK, Ridge PG. Synonymous variant rs2405442 in PILRA is associated with Alzheimer's disease and affects RNA expression by destroying a ramp sequence. Alzheimer's Association International Conference. July, 2020.
  • McKinnon LM, Miller J, Whiting MF, Kauwe JSK, Ridge PG. A Comprehensive Analysis of the Phylogenetic Signal in Ramp Sequences in 211 Vertebrates. Intelligent Systems for Molecular Biology. July, 2020.
  • Weinert A, Murcia JG, Wilson E, Kauwe JSK, Weber KS. Characterization of Mutant Chemokine Receptor CCRL2 and its Role in Inflammation and Alzheimer’s disease . BYU Library and College of Life Sciences Library Undergraduate Research Poster Competition . March, 2020.
  • Dearden L, Weinert A, Murcia JG, Wilson E, Kauwe JSK, Weber KS. Genetic Association and Characterization of Chemokine Receptor CCRL2-V180M with Alzheimer’s disease, cognitive decline, and serum cytokine levels . BYU Library and College of Life Sciences Library Undergraduate Research Poster Competition . March, 2020.
  • Kauwe JSK. University of Hawaii, Hilo. January, 2020.
  • Pickett B, Kauwe JSK, Ridge PG. Assessing long-read correction and polishing strategies for genome assembly. International Society of Computational Biology Rocky Mountain Bioinformatics Conference. December, 2019.
  • Dearden L, Weinert A, JGM, Wilson E., Kauwe JSK, Weber KS. Genetic Association and Characterization of Chemokine Receptor CCRL2-V180M with Alzheimer’s disease, cognitive decline, and serum cytokine levels. Autumn Immunology Conference 48th Annual Meeting. November, 2019.
  • Dearden L, Weinert A, JGM, Wilson E., Kauwe JSK, Weber KS. Genetic Association and Characterization of Chemokine Receptor CCRL2-V180M with Alzheimer’s disease, cognitive decline, and serum cytokine levels. Autumn Immunology Conference 48th Annual Meeting. November, 2019.
  • Ebbert M, Jensen T, Jansen-West K, Sens J, Ridge PG, Kauwe JSK, al. e. ‘Dark’ and ‘camouflaged’ genes may harbor disease-relevant variants that long-read sequencing can resolve. ASHG Annual Meeting. October, 2019.
  • Kauwe JSK. Using Population-scale Genealogical Data for Alzheimer's disease Gene Discovery. BioDesign Institute. October, 2019.
  • Kauwe JSK. Leveraging Complex Pedigrees for Rare Variant Discovery in Alzheimer’s disease. Van Andel Institute. September, 2019.
  • Murcia JDG, Avei T, Cassinat J, Weinert A, Wilson E, Weber KS, Kauwe JSK. Genetic Association and Characterization of Chemokine Receptor CCRL2-V180M with Alzheimer’s disease, cognitive decline, and serum cytokine levels . Alzheimer’s Association International Conference. July, 2019.
  • Murcia JDG, Weinert A, Wilson E, Kauwe J, Weber. Characterization of Mutant Chemokine Receptor CCBP2-V41A and its Role in Inflammation and Alzheimer’s disease. Keystone Symposia - Neural Environment in Disease: Glial Responses and Neuroinflammation. June, 2019.
  • Weinert A, Murcia JDG, Wilson E, Kauwe J, Weber KS. Characterization of Mutant Chemokine Receptor CCBP2-V41A and its Role in Inflammation and Alzheimer’s disease. American Society of Microbiology Rocky Mountain Branch Meeting. April, 2019.
  • Weinert A, Murcia JDG, Wilson E, Kauwe J, Weber KS. Characterization of Mutant Chemokine Receptor CCBP2-V41A and its Role in Inflammation and Alzheimer’s disease. BYU College of Life Science Poster Competition. March, 2019.
  • Weinert A, Murcia JDG, Wilson E, Kauwe J, Weber KS. Characterization of Mutant Chemokine Receptor CCBP2-V41A and its Role in Inflammation and Alzheimer’s disease. BYU’s 29th annual Gerontology Conference. March, 2019.
  • Murcia JDG, Weinert A, Wilson E, Kauwe J, Weber KS. Genetic Association and Characterization of CCRL2-V180M with Alzheimer’s disease, cognitive decline, and serum cytokine levels. BYU’s 29th annual Gerontology Conference. March, 2019.
  • Kauwe JSK. Pedigree-based approaches to understanding Alzheimer’s disease. University of Sharjah, Department of Biology, Chemistry and Environmental Sciences . December, 2018.
  • Weinert A, Murcia JG, Wilson E, Kauwe JSK, Weber KS. Characterization of Mutant Chemokine Receptor CCBP2-V41A and its Role in Inflammation and Alzheimer’s disease . Autumn Immunology Conference 47th Annual Meeting (oral presentation). November, 2018.
  • Murcia JG, Weinert A, Wilson E, Kauwe JSK, Weber KS. Genetic Association and Characterization of CCRL2-V180M with Alzheimer’s disease, cognitive decline, and serum cytokine levels . Autumn Immunology Conference 47th Annual Meeting (oral presentation). November, 2018.
  • Weinert A, Murcia JG, Wilson E, Kauwe JSK, Weber KS. Characterization of Mutant Chemokine Receptor CCBP2-V41A and its Role in Inflammation and Alzheimer’s disease . Autumn Immunology Conference 47th Annual Meeting (poster presentation). November, 2018.
  • Murcia JG, Weinert A, Wilson E, Kauwe JSK, Weber KS. Genetic Association and Characterization of CCRL2-V180M with Alzheimer’s disease, cognitive decline, and serum cytokine levels . Autumn Immunology Conference 47th Annual Meeting (poster presentation). November, 2018.
  • Kauwe JSK. Modern Human Genetics and the Natural Man. Nebraska Alumni Speaker's Bureau. November, 2018.
  • Kauwe JSK. Alzheimer's Disease: Myth, Facts, and the Future. Na Pu`uwai Senior Enrichment Center. October, 2018.
  • Kauwe JSK. Outreach. October, 2018.
  • Kauwe JSK. Shawn Bradley is Really, Really Tall But Why?. Life Section. September, 2018.
  • Kauwe JSK. Alzheimer's Disease: Myth, Facts, and the Future. South Peninsula Hospital. September, 2018.
  • Kauwe JSK. Why is Former NBA Player Shawn Bradley So Tall?. Top of Mind w/ Julie Rose. September, 2018.
  • Kauwe JSK. Family-based approaches to understanding the genetic basis of Alzheimer’s disease. Penn State - College of Medicine. August, 2018.
  • Murcia JG, Ferrel M, Avei T, Reid K, Weber KS, Wilson E, Grose JH, Kauwe JSK. 10 Characterization of mutant chemokine (C-C motif) receptor-like 2 (CCRL2) and its role in inflammation and Alzheimer’s disease . Alzheimer's Association International Conference. July, 2018.
  • Kauwe JSK. Alzheimer's Disease: Myth, Facts, and the Future. Na Pu`uwai Senior Enrichment Center . June, 2018.
  • Gonzalez J, Weinert A, Ferrel M, Weber KS, Kauwe JSK. Characterization of mutant chemokine (C-C motif) receptor-like 2 (CCRL2) and its role in inflammation and Alzheimer’s disease . American Society of Microbiology (Tri-Branch Meeting). April, 2018.
  • Gonzalez J, Weinert A, Ferrel M, Weber KS, Kauwe JSK. Characterization of mutant chemokine (C-C motif) receptor-like 2 (CCRL2) and its role in inflammation and Alzheimer’s disease. American Society of Microbiology (Tri-Branch Meeting). April, 2018.
  • Kauwe JSK. BYU-H NSF Trip. April, 2018.
  • Kauwe JSK. Alzheimer's Disease: Myth, Facts, and the Future. Community Meeting. March, 2018.
  • Kauwe JSK. Alzheimer's & Dementia: An Update for Attorneys. Elder Law Section. January, 2018.
  • Kauwe JSK. A unique family-based approach to identifying factors for Alzheimer's disease risk and resilience. Shiley-Marcos ADRC Neurodegeneration Seminar. November, 2017.
  • G MJ, Weber KS, Kauwe JSK. Characterization of mutant chemokine receptors and their role in inflammation and Alzheimer’s disease. Alzheimer’s Association International Conference. July, 2017.
  • Hager RL, Hedges DW, Perry CE, Nielsen B, Jeffs D, Salash M, Call VRA, Vehrs PR, Kauwe JSK. Association Between Single Nucleotide Polymorphisms and Carotid Intimal-Media Thickness in Older Adults. Annual Conference - Art and Science of Health Promotion. April, 2017.
  • Ridge PG, Wadsworth ME, Miller JB, Saykin AJ, Green RC, ADNI, Kauwe JSK. Assembly of 809 whole mitochondrial genomes with clinical, imaging, and fluid biomarker phenotyping: the Alzheimer’s Disease Neuroimaging Initiative. Biotechnology and Bioinformatics Symposium. December, 2016.
  • Kauwe JSK. RAB10 variants and Alzheimer's disease. Alzheimer's Association International Conference. 2016.
  • Kauwe JSK. Protective variants in Alzheimer's disease. Alzheimer's Association International Conference Global Advances Meeting. 2016.
  • Kauwe JSK. Alzheimer's Disease: Myths, Facts, and the Future. BYU Forum Speaker. 2016.
  • Kauwe JSK. College of Life Sciences Seminar. 2016.
  • Kauwe JSK. New approaches to understanding heritability in Alzheimer's disease. International Imaging Genetics Conference. 2016.
  • Kauwe JSK. Molecular Biology Seminar. 2016.
  • Perry CE, Hedges DW, Gale SD, EW, Kauwe JSK, Erickson LD. Association between memory functioning and latent toxoplasmosis in older adults . International Neuropsychological Society. February, 2016.
  • Perry CE, Hedges DW, Gale SD, Wilson E, Kauwe JSK, Erickson LD. Latent toxoplasmosis association with executive function in older adults . International Neuropsychological Society. February, 2016.
  • Kauwe JSK. Alzheimer's & Dementia: Information for Attorneys. Elder Law Section. January, 2016.
  • Ebbert M, Wadsworth M, Staley L, Pickett B, Initiative ADN, Kauwe JSK, Ridge PG. An Evaluation of the Necessity of PCR Duplicate Removal From Next-Generation Sequencing Data and a Comparison of Approaches. Biotechnology and Bioinformatics Symposium. December, 2015.
  • Kauwe JSK. Understanding the Genetics of Complex Traits. Biotechnology and Bioinformatics Symposium. 2015.
  • Kauwe JSK. Novel approaches to identifying protective variants for Alzheimer’s disease. Charleston Conference on Alzheimer’s Disease. 2015.
  • Kauwe JSK. Novel approaches to identifying protective variants for Alzheimer’s disease. Genetics and Genomics Sciences Department Seminar. 2015.
  • Kauwe JSK. Alzheimer’s resilience. NIH-NIA Alzheimer’s disease Summit. 2015.
  • Kauwe JSK. Linkage and WGS approaches to finding protective variants in Alzheimer’s disease. Epidemiology Center Seminar. 2014.
  • Kauwe JSK. Graduation Key Note Speaker. 2014.
  • Kauwe JSK. The genetic basis of Alzheimer’s disease: What is left and how will we find it?. Neuroscience Series. 2014.
  • Perry C, Hedges DW, D R, Nielsen B, Larson MJ, Kauwe JSK, Call VRA. Associations between telomere length and allelic variation in two groups of older adults. Gerontological Society of American meeting. November, 2014.
  • Ricks D, Perry C, Hedges DW, Nielsen B, Kauwe JSK, Call VRA. Relationship between polymorphisms associated with major depression, cognitive function, and stress regulation and telomere length in older community-dwelling adults and older competitive athletes. American Society of Microbiology Intermountain Branch. March, 2014.
  • Perry CE, Farrer TJ, Hedges DW, Nielsen B, Holt-Lunstad J, Kauwe JSK, Call VRA, Larson MJ. ApoE genotype, performance monitoring, and attention in older adults. International Neuropsychological Society . February, 2014.
  • McVey NL, Chen T, Moore TM, Ebbert MT, Madsen SR, Hallowell DM, Kauwe JSK, Thomson DM. LKB1 regulates skeletal muscle inflammation after contractions. Southwest American College of Sports Medicine Meeting. October, 2013.
  • Jensen JL, Kauwe JSK. A Constructivist Model in Introductory Biology. American Association for the Advancement of Science - Vision and Change. August, 2013.
  • Kauwe JSK. Association of genetic variants with cerebrospinal fluid protein levels of ACE, CCL2, IL6R and MMP3 risk for Alzheimer's disease. Alzheimer's Association International Conference. July, 2013.
  • Shiozawa DK, Houston D, Evans RP, Maughan PJ, Davis N, Page J, Unmack P, Elzinga D, Kauwe JSK. Greenback trout genetics and meristics studies. Greenback Cutthroat Trout Summit. July, 2013.
  • Kauwe JSK. Recent advances in diagnosis and treatment of Alzheimer's disease. Alzheimer's Association Education Conference. May, 2013.
  • Kauwe JSK. Alzheimer's Association Professional's Workshop. May, 2013.
  • Kauwe JSK. Genetics and Molecular Biology of Alzheimer's disease. International Society for Magnetic Resonance Imaging Annual Meeting. April, 2013.
  • Kauwe JSK. A novel, family-based approach to identifying Alzheimer's disease risk and protective genes. Charleston Conference on Alzheimer's Disease. March, 2013.
  • Kauwe JSK. Recent advances in diagnosis and treatment of Alzheimer's disease. Alzheimer's Association Education Conference. December, 2012.
  • Shiozawa DK, Houston DD, Elzinga DB, Smith SM, Stinger R, Maughan PJ, Kauwe JSK, Evans RP. Next generation sequencing and bioinformatics procedures identify single nucleotide polymorphisms capable of differentiating cutthroat trout subspecies. 44th Annual meeting of the Desert Fishes Council. November, 2012.
  • Kauwe JSK. Recent discoveries in Alzheimer's disease Genetics. Alzheimer's Professional's Workshop. November, 2012.
  • Kauwe JSK. Genome-wide Association studies of cerebrospinal fluid amyloid-B and tau levels. American Society of Human Genetics Meetings. October, 2012.
  • Kauwe JSK. Genetics and proteomics for understanding and diagnosing Alzheimer's Disease. Continuing Medical Education Seminar. August, 2012.
  • Shiozawa DK, Houston DD, Evans RP, Kauwe JSK, Maughan PJ, Smith SM, Elzinga DB, Stinger RB. Discovery of single nucleotide polymorphisms (SNPs) in cutthroat trout subspecies using next- generation sequencing technology. 2012 Annuual Meeting Western Division of the American Fishery Society. March, 2012.
  • Kauwe JSK. A biomarker-based approach to understanding the genetics of Alzheimer's disease. Biology Seminar. November, 2011.
  • Kauwe JSK. The present and future of Genetic Studies of Alzheimer’s Disease. Alzheimer’s Association Dementia Care Conference. October, 2011.
  • Kauwe JSK. Keynote Speaker. Biomedical Research Apprenticeship Program Closing Meeting. August, 2011.
  • Kauwe JSK. Genome-wide association studies of cerebrospinal fluid biomarkers. Alzheimer’s Association International Conference on Alzheimer’s Disease. July, 2011.
  • Kauwe JSK. Fluid biomarkers for early detection and diagnosis of Alzheimer’s disease. American Academy of Neurologists National Meeting. April, 2011.
  • Kauwe JSK. Aggregate genetic risk for AD in the Cache County Study. Epidemiology Seminar. March, 2011.
  • Kauwe JSK. Progressing from genetic association to causation in complex human disease. Molecular Life Sciences Symposium. February, 2011.
  • Kauwe JSK. The genetics basis of Alzheimer’s disease. Research Revolution. February, 2011.
  • Kauwe JSK. Using biomarkers to generate biological hypotheses for disease risk associations. Epidemiology Seminar. 2010.
  • Kauwe JSK. An endophenotype-based approach to understanding the genetics of Alzheimer's disease. LDS Life Science Research Symposium. 2010.
  • Kauwe JSK. Paths to a Career in Science. Upward Bound. 2010.
  • Kauwe JSK. Validating predicted biological effects of Alzheimer’s disease associated SNPs using cerebrospinal fluid biomarker levels. International Conference on Alzheimer's Disease. July, 2010.
  • Kauwe JSK. SNPs associated with cerebrospinal fluid tau levels influence rate of cognitive decline in Alzheimer's disease. Human Genetics Seminar Series. February, 2010.
  • Kauwe JSK. Understanding the Genetics of Alzheimer's Disease. Research Revolution. February, 2010.
  • Kauwe JSK, Goate AM, Cruchaga C. Using GWAS data to evaluate epistasis in Alzheimer's disease. Alzheimer's Disease Genetics Consortium. 2009.
  • Kauwe JSK. SNPs in CNDP1, SOAT1, TFAM and TOMM40 are associated with cerebrospinal fluid amyloid-beta levels. National Institute of Diabetes and Digestive and Kidney Diseases Network of Minority Research Investigators. www3niddknihgov/fund/other/nmriwest2009/agendahtm. 2009.
  • Kauwe JSK. Using cerebrospinal fluid biomarkers to understanding the genetic architecture of Alzhiemer's disease. Walden High School Students. 2009.
  • Kauwe JSK. Alzheimer's disease, Genome-wide association studies and endophenotypes. Biology Department and MARC program participants. 2008.
  • Kauwe JSK. Issues and progress in genetic studies of Alzheimer's disease. Biology Department and MARC program participants. 2008.
  • Kauwe JSK. Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid deposition. International Conference on Alzheimer's disease. 2008.
  • Kauwe JSK. Use of Cerebrospinal fluid biomarkers as endophenotypes for genetic studies of Alzheimer's disease. University of Utah Brain Institute. 2008.
  • Evans RP, Shiozawa DK, Kauwe JSK. Using DNA markers to investigate interbasin relationships and define species classification of stoneflies. 51st Annual meeting of the North American Benthological Society. 2003.
  • Evans RP, Hansen J, Johnson A, Kauwe JSK, Janetski D, Shiozawa DK. Can cytochrome B sequences detect a stream capture event in the Bonneville Basin? Can cytochrome B sequences detect a stream capture event in the Bonneville Basin?. 2003.
Keoni Kauwe II